MAST3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL559767	0.59	4/20
SCHEMBL2255638	0.59	4/20
SCHEMBL10207031	0.59	4/20
SCHEMBL6261492	0.47	4/20
SCHEMBL30973234	0.42	4/20
SCHEMBL24541113	0.41	4/20
SCHEMBL6268219	0.38	4/20
Tp-030N (SCHEMBL20477267)	1.00	3/20
Tp-030-1 (SCHEMBL20477342)	1.00	3/20
SCHEMBL20477276	0.91	3/20
SCHEMBL20477283	0.88	3/20
SCHEMBL20477343	0.87	3/20
SCHEMBL20477351	0.87	3/20
SCHEMBL20477265	0.86	3/20
SCHEMBL20477413	0.86	3/20
SCHEMBL20477411	0.85	3/20
SCHEMBL20477231	0.84	3/20
SCHEMBL20477363	0.84	3/20
SCHEMBL20477237	0.84	3/20
SCHEMBL20477418	0.84	3/20

Clinical trials — most relevant to MAST3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis	PHASE3	COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	PHASE3	UNKNOWN
Masitinib in Patients With Mild to Moderate Alzheimer's Disease	PHASE3	COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	PHASE3	COMPLETED
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	PHASE2/PHASE3	COMPLETED
Masitinib in Patients With Mild Alzheimer's Disease	PHASE3	NOT_YET_RECRUITING
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients	PHASE2/PHASE3	UNKNOWN
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	PHASE3	RECRUITING
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients	PHASE3	NOT_YET_RECRUITING
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	PHASE3	COMPLETED
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome	PHASE2	UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis	PHASE2	COMPLETED
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia	PHASE2	COMPLETED
Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)	PHASE1/PHASE2	UNKNOWN
Allergy and Immunology Natural History Study	nan	RECRUITING
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing	nan	COMPLETED
Cause of Unexplained Anaphylaxis	nan	ACTIVE_NOT_RECRUITING
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals	nan	COMPLETED
Mast Cell Connect: A Registry for Patients With Mastocytosis	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Pathogenesis of Physical Induced Urticarial Syndromes	nan	COMPLETED
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis	nan	RECRUITING
Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.	nan	RECRUITING
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations	nan	COMPLETED
Study of Factors Regulating Mast Cell Proliferation	nan	RECRUITING
Screening Protocol for Genetic Diseases of Allergic Inflammation	nan	COMPLETED
Serum Basal Tryptase Levels in Healthy Children	nan	COMPLETED
Persistence of Sensitization to Contrast Media	nan	NOT_YET_RECRUITING
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAST3 binder may also engage these)

Protein	Name	Similarity
MAST1	Microtubule-associated serine/threonine-protein kinase 1	1.000	landscape →
Q3U214	—	1.000	Q3U214 →
Q6AX33	—	0.999	Q6AX33 →
Q6DN90	—	0.999	Q6DN90 →
Q3U1V8	—	0.999	Q3U1V8 →
Q60610	—	0.998	Q60610 →
Q9R1L5	—	0.997	Q9R1L5 →
E9Q9W7	—	0.997	E9Q9W7 →
MAST4	Microtubule-associated serine/threonine-protein kinase 4	0.997	landscape →
Q6P0Q8	—	0.997	Q6P0Q8 →
Q9H329	—	0.997	Q9H329 →
Q810W7	—	0.997	Q810W7 →
Q9ULE0	—	0.996	Q9ULE0 →
A7MBB4	—	0.996	A7MBB4 →
Q5R8Z4	—	0.996	Q5R8Z4 →
Q9TUI4	—	0.996	Q9TUI4 →
O08774	—	0.995	O08774 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.995	landscape →
Q80TM9	—	0.995	Q80TM9 →
D3ZG83	—	0.995	D3ZG83 →
Q96PX1	—	0.995	Q96PX1 →
TESK2	Dual specificity testis-specific protein kinase 2	0.994	landscape →
Q9D3S3	—	0.994	Q9D3S3 →
Q80VW5	—	0.994	Q80VW5 →
Q6I6G8	—	0.994	Q6I6G8 →
Q96P47	—	0.994	Q96P47 →
Q4JIM5	—	0.994	Q4JIM5 →
P68907	—	0.994	P68907 →
NR4A1	Nuclear receptor subfamily 4immunitygroup A member 1	0.994	landscape →
Q8VDU5	—	0.994	Q8VDU5 →